Arrowhead Pharmaceuticals June 2026 Events
Decision brief
Answer first · skim in under a minute
Arrowhead Pharmaceuticals is set to participate in several key industry events throughout June 2026. These appearances provide a crucial opportunity for analysts, strategy, and business development teams to gain insights into the company's pipeline advancements and strategic direction.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) scheduled two June 2026 investor fireside chats in a June 2, 2026 Business Wire notice: Jefferies on June 3 at 8:10 a.m. EDT and Goldman Sachs on June 10 at 9:00 a.m. EDT. A separate June 18 wire added a June 29 cardiometabolic R&D webinar. These are calendar events for RNAi pipeline watchers, not clinical readouts by themselves.
Contents9 sections
Key Takeaways
- June 2, 2026 Business Wire release (home ID 20260602573089) listed Jefferies and Goldman Sachs fireside chats.
- Jefferies Global Healthcare Conference: June 2–4, 2026; Arrowhead chat June 3, 2026, 8:10 a.m. EDT.
- Goldman Sachs 47th Annual Global Healthcare Conference: June 8–10, 2026; Arrowhead chat June 10, 2026, 9:00 a.m. EDT.
- June 18, 2026 Business Wire release scheduled a June 29, 2026, 11:30 a.m. EDT cardiometabolic Summer Series webinar with Steven Nissen, M.D.
What did Arrowhead Pharmaceuticals announce on June 2, 2026?
Arrowhead Pharmaceuticals, Inc., based in Pasadena, California, said it would participate in the Jefferies and Goldman Sachs healthcare conferences listed above, according to the June 2, 2026 Business Wire release. The company directed stakeholders to presentation materials and webcast links, if applicable, on the Events and Presentations page under the Investors section of its website.
The notice is a participation calendar. It does not report new Phase 3 primary-endpoint results, label changes, or partnership economics. Competitive-intelligence teams should treat it as a scheduling signal, then verify any numeric claim later against primary filings.
When are the Jefferies and Goldman Sachs sessions?
Jefferies runs June 2–4, 2026, with Arrowhead’s fireside chat timed for June 3 at 8:10 a.m. EDT. Goldman Sachs runs June 8–10, 2026, with Arrowhead’s session on June 10 at 9:00 a.m. EDT. Both slots are labeled fireside chat presentations in the wire.
- Ticker referenced: NASDAQ ARWR.
- Format: fireside chat (not a late-breaking abstract slot).
- Materials path: Investors → Events and Presentations.
- Company self-description: commercial-stage RNAi developer using its Targeted RNAi Molecule (TRiM) platform.
What did the June 29 Summer Series webinar add?
On June 18, 2026, Arrowhead Pharmaceuticals announced Part I of a 2026 Summer Series of R&D webinars focused on its cardiometabolic pipeline, held June 29, 2026 at 11:30 a.m. EDT, per the June 18 Business Wire release. The company said each Summer Series webinar would run about 60–90 minutes with live webcasts and replays on the same IR Events page.
The June 29 agenda featured Steven Nissen, M.D., Chief Academic Officer for the Heart and Vascular Institute at the Cleveland Clinic, plus Arrowhead management presentations on clinical-stage RNAi candidates. External KOL commentary on disease landscape is not a substitute for trial datasets or labels.
How should BD and CI teams use these events?
Use the June chats and webinar as messaging windows on Arrowhead Pharmaceuticals’ RNAi priorities, partnering posture, and cardiometabolic narrative. Capture management language on timelines and cash runway, then reconcile any figure against SEC EDGAR filings for CIK 0000879407 (Arrowhead Pharmaceuticals, Inc.).
Do not score a fireside chat as efficacy evidence. If management cites a study, map the claim to a ClinicalTrials.gov record or peer-reviewed source before updating models. Calendar density in June 2026 also signals investor-facing cadence after earlier 2026 conference appearances, not a discrete regulatory milestone.
What remains unproven after these June disclosures?
Neither Business Wire calendar item discloses new pivotal efficacy tables, safety databases, or FDA/EMA decisions. The Summer Series webinar format can include forward-looking statements; Arrowhead’s own safe-harbor language points readers to Form 10-K and 10-Q risk factors for actual results that may differ.
Analysts should separate (1) confirmed schedule facts in the wires from (2) any oral commentary that still needs primary-source corroboration. No claim in these releases establishes comparative superiority versus other RNAi or antisense cardiometabolic programs.
Related NovaPharma coverage
- Arrowhead cardiometabolic data coverage
- Arrowhead clinical data at EAS congress
- BioCryst HAE data at EAACI 2026
Frequently Asked Questions
Which June 2026 conferences did Arrowhead Pharmaceuticals schedule?
In a June 2, 2026 Business Wire release, Arrowhead Pharmaceuticals scheduled a Jefferies Global Healthcare Conference fireside chat on June 3, 2026 at 8:10 a.m. EDT and a Goldman Sachs 47th Annual Global Healthcare Conference fireside chat on June 10, 2026 at 9:00 a.m. EDT.
What R&D webinar did Arrowhead announce for late June 2026?
On June 18, 2026, Arrowhead Pharmaceuticals said Part I of its 2026 Summer Series of R&D Webinars would cover its cardiometabolic pipeline on June 29, 2026 at 11:30 a.m. EDT, featuring Steven Nissen, M.D., and Arrowhead management.
Do investor conference chats equal clinical readouts?
No. Fireside chats disclose schedules and may include commentary, but they are not substitutes for peer-reviewed data, ClinicalTrials.gov records, or SEC filings that lock efficacy, safety, or financial claims.
Primary Sources
Arrowhead Pharmaceuticals pipeline snapshot
One-screen view of active programs, phases, and recent catalysts from public sources.
Sources & references 1 primary sources
Sources verified at publication. See our editorial policy and data sources.
This article follows our editorial standards. Report a correction via editorial contact.
